To download the latest issue
Nov 14th, 2012
Canada’s GenePOC eyes 2014 for Point-of-Care MDx System, Group B Strep Test
CANADIAN MOLECULAR DIAGNOSTICS firm Gene- POC has completed technical development of its benchtop, point-of-care molecular diagnostic system and disposable test cartridges, and has commenced clinical feasibility studies of the platform, company executives said this week
In addition, the company hopes to begin clinical trials for its first commercial assay – a molecular test to detect group B streptococcus in pregnant women – by the end of 2013, with the hopes of launching the assay and its system, called GenePOC Diagnostics, by the end of 2014.
Reprinted with permission of GenePOC
More MEDTECH news